BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the
+1 857-302-5663 or +1 857-302-7596
Source: BeiGene, LTD.